Page 13 - இடைக்கால பகுப்பாய்வு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இடைக்கால பகுப்பாய்வு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இடைக்கால பகுப்பாய்வு Today - Breaking & Trending Today

Le vaccin russe est aussi efficace que les autres

Le vaccin russe est aussi efficace que les autres
lessentiel.lu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lessentiel.lu Daily Mail and Mail on Sunday newspapers.

United States , France General , United Kingdom , Ministry Of Health , Al Qahirah , British Columbia , New School , To Roma , Arkhangel Skaya Oblast , Western Australia , New York , City Of , Town Hall , Israel General , Angela Merkel , Mohammad Javad Zarif , Luis Arce , Nicolas Maduro , Ian Jones , Biontech Africa , Sebastiana Kurz , Cyril Ramaphosa , Joe Biden , Palestinian Mahmoud Abbas , Qian Keming , Justin Trudeau ,

«Un vaccin pour tous les Français à la fin de l'été»

«Un vaccin pour tous les Français à la fin de l'été»
lessentiel.lu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lessentiel.lu Daily Mail and Mail on Sunday newspapers.

France General , United Kingdom , Ministry Of Health , Al Qahirah , British Columbia , New School , United States , To Roma , Arkhangel Skaya Oblast , Western Australia , New York , City Of , Israel General , Mohammad Javad Zarif , Nicolas Maduro , Biontech Africa , Sebastiana Kurz , Joe Biden , Qian Keming , Justin Trudeau , Vladimir Putin , Polly King , Lopez Obrador , Roberto Fico , Andrew Cuomo , Yoshihide Suga ,

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released
An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months.
The interim analysis assessed 468 cases of symptomatic COVID-19 among 44,325 adult volunteers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States. The investigational vaccine was reportedly 66% effective at preventing the study’s combined endpoints of moderate and severe COVID-19 at 28 days post-vaccination among all volunteers, including those infected with an emerging viral variant. Moderate COVID-19 was defined as laboratory-confirmed SARS-CoV-2 plus either one of the following: ....

South Africa , United States , Rio De Janeiro , Estado Do Rio , University Of Alabama , Oswaldo Cruz , Rio Grande Do Sul , Beatriz Grinsztejn , Glendae Gray , Paula Goepfert , Human Service Office Of The , National Institute Of Allergy , Evandro Chagas National Institute Of Infectious Diseases , Janssen Pharmaceutical Companies Of Johnson , Prevention Network Co , Vaccine Trials Network , Oswaldo Cruz Foundation , Alabama Vaccine Research Clinic , National Institutes Of Health , Biomedical Advanced Research , Human Services , Us Department Of Health , Drug Administration , Development Authority , Laboratory Of Clinical Research , Janssen Pharmaceuticals ,

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from full study population of 350 patients and results of second study of KB109 are expected in the first quarter of 2021 LEXINGTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 hours of testing positive for COVID-19 to either receive Supportive Self Care (SSC) or SSC plus Microbiome Metabolic Therapy (MMT™) candidate KB109 for two weeks and then followed for an additional three weeks. The planned interim analysis comprised approximately half of the total study population (n=176) and showed that KB109 was well tolerated, with a safety profile ....

Kaleido Biosciences , Clinical Studies , Study Population , Interim Results , Microbiome Metabolic Therapies , Interim Analysis , காலேதோ உயிர் அறிவியல் , மருத்துவ ஆய்வுகள் , படிப்பு பாப்யுலேஶந் , இடைக்கால முடிவுகள் , இடைக்கால பகுப்பாய்வு ,